X

Latest News

 
  • Blood Processing Methods Affect Microparticles and mtDNA Linked to Blood Transfusion Reactions

    04/11/2016

    OTTAWA, ON – Scientists from Blood Systems Research Institute in San Francisco, California, and Canadian Blood Services’ Centre for Innovation lab in Edmonton, Alberta, report for the first time that specific red blood cell manufacturing methods may be less damaging to cells than others. This finding could help reduce adverse reactions in transfusion recipients and may impact the future of how blood is collected in North America and around the world.

  • Countdown to a Cure, UCSF Magazine, Summer 2016

    04/01/2016

    Spurred by three decades of momentum and fresh funding, scientists mount a major effort to finally defeat AIDS.

  • BSRI Launches Denver Campus, Welcomes Dr. Larry J. Dumont as Senior Investigator and Associate Director

    01/27/2016

    “Under Larry’s direction, BSRI-Denver will be an important participant and contributor in the development and evaluation of new methods, devices and biological products in transfusion medicine,” said Michael Busch, M.D., Ph.D., Blood Systems Senior Vice President for Research and Scientific Programs and BSRI Co-Director. “BSRI has a strong reputation for innovative scientific research and policy development, built over more than half a century. The Denver initiative, with Larry’s leadership and Bonfils’ exceptional facilities, brings BSRI squarely into the development arena of R&D with the practical application of scientific knowledge to make a real difference in the lives of patients who receive transfusions.”

  • Scientists Identify Effective and Novel Mechanisms to Block Chikungunya Virus

    12/10/2015

    Funded by grants from the National Institutes of Health, scientists at Blood Systems Research Institute (BSRI) in San Francisco and the Washington University School of Medicine in St. Louis have found that neutralizing antibodies that engage epitopes including residue E2-W64 are highly potent at inhibiting the virus in mice, due to the importance of E2-W64 in pathogenicity. Furthermore, these antibodies prevent CHIKV from both entering and exiting cells, whereas prior studies of neutralizing antibodies to CHIKV and multiple other classes of viruses have focused on the capacity to block viruses from entering a cell.

  • amfAR Establishes San Francisco-Based Institute for HIV Cure Research

    11/30/2015

    NEW YORK, November 30, 2015 – amfAR, The Foundation for AIDS Research, today announced the establishment of the amfAR Institute for HIV Cure Research, an innovative collaborative enterprise based at the University of California, San Francisco (UCSF). As the cornerstone of amfAR’s $100 million cure research investment strategy, the aim of the Institute will be to develop the scientific basis of a cure for HIV by the end of 2020.

  • Viruses the Focus of the 2013 BSRI Retreat

    Viruses the Focus of the 2013 BSRI Retreat

    09/13/2013

    BSRI's annual scientific retreat took place on September 13 at San Francisco's historic Fort Mason Center. Associate Investigator Graham Simmons organized this virus-focused event which included presentations by BSRI investigators Eric Delwart and Satish Pillai. Joining our investigators were three invited speakers, William Robinson, MD, PhD (Stanford University), Sean Amberg, PhD (SIGA Technologies) and William Switzer, MPH (CDC Division of HIV/AIDS Prevention).